General
Preferred name
LISINOPRIL
Synonyms
Lisopress ()
Acemin ()
Carace ()
MK-521 ()
MK-521 dihydrate ()
Renacor ()
Linopril ()
Zestril ()
Prinivil ()
Lisipril ()
MK-521 (dihydrate)Lisinopril ()
Lisinopril (Zestril) ()
LISINOPRIL ANHYDROUS ()
Lisinopril (dihydrate) ()
MK-521 (dihydrate) ()
Lisinopril dihydrate ()
Ranolip ()
Lisinopril component of prinzide ()
Lisinopril hydrate ()
NSC-751176 ()
NSC-758151 ()
Qbrelis ()
Lisinopril component of zestoretic ()
Lisinopril ()
Lisinopril-d5 ()
P&D ID
PD001442
CAS
83915-83-7
76547-98-3
77726-95-5
1356905-39-9
Tags
available
drug
Approved by
FDA
First approval
1987
Drug indication
Hypertension
Coronavirus Disease 2019 (COVID-19)
azoospermia
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Lisinopril was the third ACE inhibitor (after and ) to be approved for clinical use. Chemically it is the lysine analogue of enalapril. Unlike other ACE inhibitors, it is not a prodrug and is excreted unchanged in the urine. (GtoPdb)
PRICE 29
PRICE 29
DESCRIPTION Lisinopril is an angiotensin converting enzyme inhibitor (ACEI), preventing the conversion of angiotensin I to angiotensin II. Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients <6 years, and as an adjunct therapy for heart failure. (Enamine Bioactive Compounds)
DESCRIPTION Lisinopril (Prinivil), the angiotensin-converting enzyme (ACE) inhibitor, is used primarily in the treatment of high heart failure, blood pressure, and heart attacks. It is also used for preventing eye and kidney complications in people with diabetes. (TargetMol Bioactive Compound Library)
DESCRIPTION Lisinopril dihydrate (MK-521) is an orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. (TargetMol Bioactive Compound Library)
Compound Sets
24
AdooQ Bioactive Compound Library
A11876
Cayman Chemical Bioactives
28520
ChEMBL Approved Drugs
CHEMBL1237
CHEMBL419213
ChEMBL Drugs
CHEMBL1237
CHEMBL419213
Drug Repurposing Hub
DrugBank
DB00722
DrugBank Approved Drugs
DB00722
DrugCentral
1587
DrugCentral Approved Drugs
1587
DrugMAP
DM54D1G
DMUOK4C
DrugMAP Approved Drugs
DMUOK4C
Enamine Bioactive Compounds
EBC-02057
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS100365
Guide to Pharmacology
6360
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1237
MedChem Express Bioactive Compound Library
HY-18206
HY-18206A
NCATS Inxight Approved Drugs
7Q3P4BS2FD
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
lisinopril-zestril
TargetMol Bioactive Compound Library
T21418
T0706
The Spectrum Collection
External IDs
80
Properties
(calculated by RDKit )
Molecular Weight
405.23
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
4
Rotatable Bonds
12
Ring Count
2
Aromatic Ring Count
1
cLogP
1.24
TPSA
132.96
Fraction CSP3
0.57
Chiral centers
3.0
Largest ring
6.0
QED
0.38
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
ACE
MRP1
ACE, ACE2
Angiotensin-converting Enzyme (ACE)
ACE,RAAS
MOA
MRP inhibitor
RAAS inhibitor
angiotensin converting enzyme inhibitor
Indication
hypertension, congestive heart failure, diabetes mellitus
Disease Area
cardiology, endocrinology
Therapeutic Class
Antihypertensive Agents
Antiviral Agents
Pathway
Endocrinology/Hormones
Immunology/Inflammation
Metabolic Enzyme/Protease
Source data